Endpoints collected data on more than 350 CEO compensation packages, covering a wide range of pharma, biotech, and life sciences companies. All told, the 20 largest earners made over $725 million in 2022 — an average package of $36.4 million. Three brought in paydays over $50 million, and one CEO broke the $100 million mark.
Unlock this story instantly and join 169,900+ biopharma pros reading Endpoints daily — and it’s free.
Illumina’s chairman has been ousted from the company’s board, a partial win for activist investor Carl Icahn, who is still likely to put the future leadership and direction of the DNA sequencing giant into question.
The vote to replace chairman John Thompson with Andrew Teno has been the climax of a proxy fight brought by Icahn after Illumina’s stock slide and decision to buy the cancer-testing company Grail. The referendum saw both sides make pitched arguments for the future of the $32 billion maker of DNA sequencing machines.
Unlock this story instantly and join 169,900+ biopharma pros reading Endpoints daily — and it’s free.
Rich Horgan’s quest to create a custom gene therapy for his brother, Terry, ended in tragedy. But Horgan doesn’t believe it’s the end of the story.
Terry, a 27-year-old patient with Duchenne muscular dystrophy, died last October just eight days after receiving the therapy in a clinical trial in which he was the only participant. The case raised questions about the safety of certain gene therapies and what would happen to other drug programs under a nonprofit that Horgan created, called Cure Rare Disease.
Unlock this story instantly and join 169,900+ biopharma pros reading Endpoints daily — and it’s free.
This year’s list of 20 biotech leaders under the age of 40 includes a huge range of ambitions. Some of our honorees are planning to create the next big drug giant. Others are pushing the bounds of AI. One is working to revolutionize TB testing. All are compelling talents who are still young in age, but already far along in achievement.
And, as in years past, we went over. The 20 are actually 22 because of two double profiles that reflect how important teamwork is in the industry. As one of our honorees, Joe Illingworth of DJS Antibodies, told me in our interview, “It takes a village to raise a biotech.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 169,900+ biopharma pros reading Endpoints daily — and it’s free.
The US House of Representatives has turned a sharp eye to drug shortages over the past few months, with hearings and new caucuses to try and dampen the situation, but another bipartisan letter sent yesterday to FDA aims to keep the pressure up on cancer drug shortages.
Reps. Debbie Dingell (D-MI) and Tim Walberg (R-MI) penned the letter to FDA Commissioner Rob Califf, expressing concerns around the shortages of two commonly used chemotherapies used to treat cancer, known as cisplatin and carboplatin, which are used for lung, gynecologic and breast cancers, as well as methotrexate, which is used in treating other forms of cancer.
Unlock this story instantly and join 169,900+ biopharma pros reading Endpoints daily — and it’s free.
The manufacturing spaces for any type of DNA work may bring up images of a large, windowless, warehouse-type building, or a more modern facade donned with glass, but one manufacturer is converting an old Victorian-style building into a new manufacturing site.
Touchlight, a UK-based producer of a proprietary enzymatic DNA product it calls “doggybone DNA,” or dbDNA, which has a schematic structure that’s linear and double-stranded, giving the appearance of a dog bone, has opened the doors to a redeveloped and expanded manufacturing facility that is housed within a former Victorian-era waterworks building on the River Thames in the Borough of Hampton in West London. According to a release, the expanded facility has tripled Touchlight’s manufacturing output and can produce more than 8 kg of DNA product a year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 169,900+ biopharma pros reading Endpoints daily — and it’s free.
The investment will total CA$701 million ($515.9 million) over the next eight years, with the funding going toward building new infrastructure to develop antibody-based medicines. This includes a site to develop and manufacture antibody medicines through the clinic.
As Novo Nordisk and Pfizer disclose some data on their oral weight loss drugs in Phase III and II, respectively, Eli Lilly is beefing up its stance in the obesity field with three late-stage clinical trials of its next-generation GLP-1 agonist orforglipron.
The moves, disclosed in updates to the federal clinical trials database this week, put the Indianapolis drugmaker ahead of Pfizer, whose science chief has said the company will “cherry-pick” which of its mid-stage candidates to take deeper into the clinic after data late this year or early next.
Unlock this story instantly and join 169,900+ biopharma pros reading Endpoints daily — and it’s free.
The new facility, which was set up with assistance from the Singapore Economic Development Board, aims to provide vaccine fill-finish capabilities and other development and manufacturing services. It will also have a fill-finish line for small and large molecules.
Thermo Fisher already has a presence in Singapore with several laboratories that focus on bioprocessing, life science and analytical services.
Unlock this story instantly and join 169,900+ biopharma pros reading Endpoints daily — and it’s free.
This content was originally published here.
